The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Rapid Response Innovation Awards, 2014Novel Mechanism for Death of Dopaminergic Neurons in a Model for Parkinson’s Disease
Study Rationale:
Parkinson’s disease (PD) is due in large part to the death of dopaminergic neurons in a part of the brain called the substantia nigra. An understanding of why, as we... -
Research Grant, 2015Unified Dyskinesia Rating Scale: Application for FDA Designation as a Preferred Scale for Assessing Dyskinesia in Parkinson’s Disease
Study Rationale:
Several scales are available for the rating of dyskinesia in Parkinson’s disease, and the designation of a single preferred scale for studies of new treatments will allow different... -
Target Validation, 2015NLRP3 Inflammasome in Parkinson's Disease
Objective/Rationale:
The goal of this proposal is to validate the NLRP3 inflammasome as a therapeutic target in Parkinson’s disease. Unlike circulating inflammatory mediators whose complex... -
Research Grant, 2015Cell-to-Cell Transport of Alpha-Synuclein
Study Rationale:
In Parkinson’s disease, the protein alpha-synuclein changes shape, and we think it transfers around the brain. We want to see if we can recreate this in non-human... -
Research Grant, 2015Selective mGluR3 Positive Allosteric Modulators as Neuroprotective Agents for Parkinson's Disease Supplement
Study Rationale:
mGluR3 is a novel target leading to neuroprotection through production of neurotrophic factors. We have recently demonstrated that selective mGluR3 positive... -
Research Grant, 2015Pre-clinical Evaluation of Neuroprotective Small Molecule Erythropoietin Receptor Agonists in the Treatment of Parkinson’s Disease Supplement
Study Rationale:
STATegics has discovered small molecules that selectively activate the tissue-protective erythropoietin (EPO) receptor, but not the EPO receptor that plays a role in...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.